Sabra Health Care REIT (SBRA) Price to Sales (2011 - 2026)

Sabra Health Care REIT has reported Price to Sales for 16 years, with the latest figure at 21.13 in Q2 2026.

• On a quarterly basis, Price to Sales fell 9.61% year-over-year to 21.13 in Q2 2026; TTM through Jun 2026 was 5.8, a 3.87% decrease from a year earlier, with the FY2025 full-year figure at 6.15, up 5.17% from the prior year.
• Price to Sales was 21.13 for Q2 2026 at Sabra Health Care REIT, down from 21.87 in the prior quarter.
• The five-year high for Price to Sales was 24.74 in Q3 2024, with the low at 16.48 in Q1 2023.
• Average Price to Sales over 5 years is 21.03, with a median of 21.11 recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Price to Sales decreased 24.32% in 2022, then advanced 24.42% in 2024.
• Over 5 years, Price to Sales stood at 17.4 in 2022, then grew by 16.05% to 20.2 in 2023, then climbed by 11.73% to 22.57 in 2024, then dropped by 0.31% to 22.5 in 2025, then fell by 6.07% to 21.13 in 2026.
• The last three Price to Sales figures came in at 21.13 (Q2 2026), 21.87 (Q1 2026), and 22.5 (Q4 2025), per Business Quant data.